Education
About Us
Working with TipRanks
Follow Us
TriSalus Life Sciences (TLSI)
NASDAQ:TLSI
TLSI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.42 - $5.88
Previous CloseN/A
Volume4.84K
Average Volume (3M)97.62K
Market Cap
$257.32M
Enterprise Value$186.47M
Total Cash (Recent Filing)$13.00M
Total Debt (Recent Filing)$33.12M
Price to Earnings (P/E)―
Beta0.71
Next Earnings
Nov 18, 2025EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.27
Shares Outstanding49,867,280
10 Day Avg. Volume122,173
30 Day Avg. Volume97,619
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.72
Enterprise Value/Revenue5.80
Enterprise Value/Gross Profit6.78
Enterprise Value/Ebitda-8.47
Forecast
1Y Price Target
$10.29Price Target Upside99.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
Financial GuidanceThe company reiterated guidance for revenue growth in 2025 of 50%+, which is expected to be driven by continued commercial efforts in liver-directed therapies.
Product DevelopmentTriNav system adoption continues to expand as more real-world data and health economic research demonstrate improved clinical outcomes, particularly in complex disease/patient settings and has more favorable economics for providers.
Bears Say
Cash Flow ExpectationsInvestments in TriNav commercial efforts have led the company to no longer expect cash flow positivity in FY25, now expected in the first half of 2026.
Financial PerformanceGross margin of 83.9% missed our 86% estimate, and adjusted EBITDA of ($5.3M) also missed our ($4.3M) estimate.
TriSalus Life Sciences News
TLSI FAQ
What was TriSalus Life Sciences’s price range in the past 12 months?
TriSalus Life Sciences lowest stock price was $3.42 and its highest was $5.88 in the past 12 months.
What is TriSalus Life Sciences’s market cap?
TriSalus Life Sciences’s market cap is $257.32M.
When is TriSalus Life Sciences’s upcoming earnings report date?
TriSalus Life Sciences’s upcoming earnings report date is Nov 18, 2025 which is in 74 days.
How were TriSalus Life Sciences’s earnings last quarter?
TriSalus Life Sciences released its earnings results on Aug 12, 2025. The company reported -$0.27 earnings per share for the quarter, missing the consensus estimate of -$0.207 by -$0.063.
Is TriSalus Life Sciences overvalued?
According to Wall Street analysts TriSalus Life Sciences’s price is currently Undervalued.
Does TriSalus Life Sciences pay dividends?
TriSalus Life Sciences does not currently pay dividends.
What is TriSalus Life Sciences’s EPS estimate?
TriSalus Life Sciences’s EPS estimate is -0.14.
How many shares outstanding does TriSalus Life Sciences have?
TriSalus Life Sciences has 49,867,280 shares outstanding.
What happened to TriSalus Life Sciences’s price movement after its last earnings report?
TriSalus Life Sciences reported an EPS of -$0.27 in its last earnings report, missing expectations of -$0.207. Following the earnings report the stock price went up 8.219%.
Which hedge fund is a major shareholder of TriSalus Life Sciences?
Currently, no hedge funds are holding shares in TLSI
TriSalus Life Sciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.29 (99.81% Upside)
$10.29 (99.81% Upside)
Blogger Sentiment
Neutral
TLSI Sentiment 50%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 265.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 0.5%
Last 30 Days ▲ 0.5%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
0.00%
12-Months-Change
Fundamentals
Return on Equity
271.41%
Trailing 12-Months
Asset Growth
27.40%
Trailing 12-Months
Company Description
TriSalus Life Sciences
TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. It also develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company is based in Westminster, Colorado.
TLSI Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a generally positive outlook with significant revenue growth, successful product launches, and strategic capital raises. However, there were challenges with gross margin decline, increased administrative expenses, and a delay in achieving EBITDA positivity. Overall, the positive aspects of growth and expansion outweigh the financial setbacks.View all TLSI earnings summariesTLSI Stock 12 Month Forecast
Average Price Target
$10.29
▲(99.81% Upside)
Technical Analysis
Ownership Overview
30.48% Insiders
1.48% Mutual Funds
11.51% Other Institutional Investors
54.50% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---